Net worth tracking
Login Sign Up
Become a Premium Member
  • All Opinions
  • Top Picks
  • Experts
  • Companies
  • Discover
Watch List
Home » Stock Lists

Top Biotech and Pharma Stocks to Bet on Cancer Cure & Control

Melisa R. H. Posted On October 10, 2019
0
0
Shares
  • Share On Facebook
  • Tweet It

Cancer fighting drugs and therapy companies are poised to profit from long term aging trends of the population as well as the rise of cancer in general. There are now companies that are trying to personalize treatments with gene therapy.

Here are Canadian and US companies that are producing innovative methods to control and cure cancer.

👨‍⚕️ Healthcare

Canada Stocks

Oncolytics Biotech (ONC-T)
A company that specializes in treating solid tutors. There is still a long way to go but the product has huge potential.

Oncolytics Biotech (ONC-T) — Stockchase
Oncolytics Biotech (ONC-T) — Stockchase

The technicals do not look good at all – with a decline lasting over the past two months. He would not touch this one at all. A 50 day moving average would be a buy signal if it can trade back above it.

stockchase.com stockchase.com

Concordia International Corp (CXR-T)
The company focuses on treating ADHD, cancer and asthma. They went through a restructuring, along with many other Canadian drug manufacturers.

Concordia International Corp (CXR-T) — Stockchase
Concordia International Corp (CXR-T) — Stockchase

Likes turnarounds, but it’s not ready. Want to see two things: 1) the stock hitting a 52-week high, and 2) the numbers moving in the right direction. Don’t do anything until then. Odds are this is going to zero.

stockchase.com stockchase.com

Medx Health Corp. (MDX-X)
A company that has recently changed their President and CEO. It is a medical device manufacturer that helps diagnose skin cancer, and they are now entering Spanish-speaking countries.

Medx Health Corp. (MDX-X) — Stockchase
Medx Health Corp. (MDX-X) — Stockchase

Brazilian order? He owns warrants and his wife works as a consultant for them. They have orders for 500 units for a melanoma testing product. The delivery is subject to approval by authorities in Brazil. This could lead to hardware sales by June and revenues that begin to show up in Q4. The company thinks…

stockchase.com stockchase.com

U.S Stocks

Amgen Inc. (AMGN-Q)
A developer and manufacturer of biotechnology based therapy. They have several cancer fighting drugs in their repertoire including a new colorectal cancer drug. They have surpassed earning estimates in the last year and pays a dividend of 3%.

Amgen Inc. (AMGN-Q) — Stockchase
Amgen Inc. (AMGN-Q) — Stockchase

(A Top Pick Nov 03/20, Up 17.6%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with AMGN is progressing well. We now recommend trailing up the stop (from $218) to $228.

stockchase.com stockchase.com

Celgene Corp (CELG-Q)
An American biotech company that specializes in cancer and inflammatory disorder therapy. They are starting the process of merging with BMY-N. A good cash flow generator.

Celgene Corp (CELG-Q) — Stockchase
Celgene Corp (CELG-Q) — Stockchase

(A Top Pick Dec 03/18, Up 47%) Celgene had made a number of mis-steps, including management applying for multiple FDA approvals. One thing he really liked about the acquisition was the price it was bought. The acquisition by BMY helped them diversify and it seems to be going well.

stockchase.com stockchase.com

Bristol Myers Squibb (BMY-N)
The company has several blockbuster immunotherapy drugs in their pipeline, as well as some chemotherapy products for leukaemia. The company has announced plans to acquire Celgene that will add several other high profile drugs.

Bristol Myers Squibb (BMY-N) — Stockchase
Bristol Myers Squibb (BMY-N) — Stockchase

(A Top Pick Dec 29/21, Up 21.6%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with BMY is progressing well. To remain disciplined, we recommend trailing up the stop (from $68) to $72.

stockchase.com stockchase.com

Pfizer Inc (PFE-N)
One of the largest pharmaceutical companies in the world. It is currently in its seasonal weakness which is mid-October. It has enjoyed long term support levels and is consolidating well.

Pfizer Inc (PFE-N) — Stockchase
Pfizer Inc (PFE-N) — Stockchase

The entire drug sector hasn't been investable since the 1990s, because governments control drug prices and patent expiries. Pfizer is struggling to replace drugs coming off patent, like their cholesterol drug. It's really tough. It's a defensive sector, so the drug companies will hold up better and offer dividend growth.

stockchase.com stockchase.com

AbbVie Inc. (ABBV-N)
Their blood cancer drug is projected to be one of the top best selling drugs in the world in the near future. The company also has other oncology drugs such as a top-selling immunology drug called Humira. They are currently in the process of acquiring Allergan.

AbbVie Inc. (ABBV-N) — Stockchase
AbbVie Inc. (ABBV-N) — Stockchase

Pays a 4% yield and just started working on this Allergen franchise they just bought. Their core drugs keep selling. This will go higher.

stockchase.com stockchase.com

Johnson & Johnson (JNJ-N)
A global medical devices, pharmaceutical and consumer goods company. Their drugs are doing well and the company remains very profitable but volatile. They are going through a litigation for opiates and a ruling against their anti-psychotic drug.

Johnson & Johnson (JNJ-N) — Stockchase
Johnson & Johnson (JNJ-N) — Stockchase

Healthcare is defensive name in current market. Upcoming spinoffs planned of business units will change profile of company. Long history of rising dividends and solid financial metrics. Is a good company to hold for the long term. Current share price is attractive.

stockchase.com stockchase.com

Novartis AG (NVS-N)
One of the world’s largest pharmaceutical company based out of Switzerland. They sold off their ophthalmology business and are refocusing on generic drugs. The company also has many drugs that are close to approval that could become blockbuster drugs.

Novartis AG (NVS-N) — Stockchase
Novartis AG (NVS-N) — Stockchase

Made big money by selling off one division. Decent pipelines. Looking to sell off generic division. Dividend grows, share buybacks. Healthcare has become front and centre, and that's not going away. Safe haven. Underpriced at these levels. Yield is 3.55%. (Analysts’ price target is $88.96)

stockchase.com stockchase.com

GlaxoSmithKline PLC (GSK-N)
A British pharma company that is refocusing away from consumer products to pharmaceuticals. The company is doing well with 5% dividend. However, there is a hard brexit risk.

GlaxoSmithKline PLC (GSK-N) — Stockchase
GlaxoSmithKline PLC (GSK-N) — Stockchase

They're spinning off their consumer products division, so GSK has historically traded at a discount with slower growth than other drugmakers. New management has turned around the pharmaceuticals side and make good consumer products. Aging populations in the west is a tailwind.

stockchase.com stockchase.com

Astrazeneca P L C (AZN-N)
A well diversified and global pharmaceutical company that specializes in oncology. They pay a great dividend and are focusing on less price-sensitive areas.

Astrazeneca P L C (AZN-N) — Stockchase
Astrazeneca P L C (AZN-N) — Stockchase

Health care is back in favour, is defensive, and has growth characteristics. AZN has a great pipeline including some drugs that are difficult to make. It trades at an attractive valuation, has a solid balance sheet, good dividend and is liquid. Buy 3, Hold 3, Sell 0. (Analysts’ price target is $72.40)

stockchase.com stockchase.com

Gilead Sciences Inc. (GILD-Q)
An American biopharmaceutical company. They consolidated for the last year and a half. The company is doing well, with a 4% yield. They have a history of blockbuster drugs with Hepatitis C and HIV.

Gilead Sciences Inc. (GILD-Q) — Stockchase
Gilead Sciences Inc. (GILD-Q) — Stockchase

(A Top Pick Oct 27/20, Up 6.6%)Stockchase Research Editor: Michael O’Reilly Our PAST TOP PICK with GILD has triggered its stop at $64. To remain disciplined, we recommend covering the position at this time. We will look for better opportunities.

stockchase.com stockchase.com

Regeneron Pharmaceuticals Inc (REGN-Q)
A biotech company with good free cash flow. They have some drugs for niche markets. Their earnings don’t come from one specific sector of their activity.

Regeneron Pharmaceuticals Inc (REGN-Q) — Stockchase
Regeneron Pharmaceuticals Inc (REGN-Q) — Stockchase

Large cap biotech. Its two franchises are dominant: macular degeneration and atopic dermatitis. One of the best at R&D. Proven ability to execute. One of the better growth profiles for next 3-5 years. Bit of volatility around reimbursement. Decent valuation. No dividend.

stockchase.com stockchase.com

CRISPR Therapeutics AG (CRSP-Q)
A smaller company that is developing gene medications. They have a gene-editing tool that has the potential to cure several diseases, including some cancers.

CRISPR Therapeutics AG (CRSP-Q) — Stockchase
CRISPR Therapeutics AG (CRSP-Q) — Stockchase

Their gene-editing biotechnology has lots of promise, but it's too early to tell, speculative. Buying this is a lottery ticket.

stockchase.com stockchase.com

Varian Medical Systems (VAR-N)
The company specializes in radiation therapy equipment to treat cancer. The trend for cancer radiation therapy is still positive and analysts think there will be an up-tick in sales.

Varian Medical Systems (VAR-N) — Stockchase
Varian Medical Systems (VAR-N) — Stockchase

(A Top Pick Aug 29/14. Up 2.34%.) Radiation therapy equipment for treating cancer. Have been affected a little by foreign exchange rates. These are big ticket purchases, so she expects purchases have been delayed, but she has seen this come back. On the emerging-market side, it is a little bit more challenging. Still thinks the…

stockchase.com stockchase.com

Merck & Company (MRK-N)
Their main drugs are for treating diabetes and oncology. They have a great pipeline of new drugs that are coming up and will drive revenues over the long term. They pay a dividend of 2.65%

Merck & Company (MRK-N) — Stockchase
Merck & Company (MRK-N) — Stockchase

(A Top Pick Mar 24/22, Up 5.7%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with MRK has triggered its stop at $855. To remain disciplined we recommend covering the position at this time. This will result in a net investment gain of 8%, when combined with previous buy recommendations.

stockchase.com stockchase.com

Eli Lilly & Co. (LLY-N)
A global pharmaceutical company that recently made an acquisition in oncology. It has been one of the best growth companies with a rate of 10% EPS.

Eli Lilly & Co. (LLY-N) — Stockchase
Eli Lilly & Co. (LLY-N) — Stockchase

LLY vs. NVO NVO is focused on weight loss and diabetes. One issue is the liquidity, as it doesn't work well for his covered call strategy. Still fairly expensive. LLY had great weight reduction results recently. LLY is at a discounted valuation, a more diversified business, and exposure to Alzheimer's. He prefers LLY, but you'd…

stockchase.com stockchase.com

Abbott Labs (ABT-N)
A diversified healthcare company. It sells generic drugs to emerging markets. They also have medical devices and are diversified globally. A very safe play, especially considering that they have raised dividends for 47 years straight. Yield of 1.50%.

Abbott Labs (ABT-N) — Stockchase
Abbott Labs (ABT-N) — Stockchase

(A Top Pick May 31/22, Down 10.4%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with ABT has triggered its stop at $105. To remain disciplined we recommend covering the position at this time. This will result in a net investment loss of 12%, when combined with previous buy recommendations.

stockchase.com stockchase.com

0
Shares
  • Share On Facebook
  • Tweet It




Trending Now
Air Canada, Shell plc and 19 Stock and 1 ETF Top Picks (Jun 17-23)
Melisa R. H. June 24, 2022
Spectral Med Inc and More at 52-week Highs & Lows (Jun 15-21)
Melisa R. H. June 22, 2022
Read Next

American markets were excited

  • We're the Stock Chasers
    Hi! We are the Stock Chasers. We write about investing and finance tools we love. We’re passionate about fintech and we invest almost all our affiliate and advertising revenues into the development of Stockchase and Wealthica. We hope you enjoy the stock ideas and product reviews!
  • Top Reviews

    • Questrade Review: Pros & Cons of Trading with Questrade Canada (2021)
      8.5
    • Questrade vs Others | The Review Competitors Don’t Want you to Read (2021)
      7.4
    • The Ugly Truth About Identity Theft – Free Credit Report
      7
  • Popular Posts

    • Air Canada, Shell plc and 19 Stock and 1 ETF Top Picks (Jun 17-23)
    • Spectral Med Inc and More at 52-week Highs & Lows (Jun 15-21)
    • 3 defensive stocks to find stability with your money
    • Greenspace Brands Inc, BlackBerry and More Earnings Reports this Week (Jun 20-24)
    • Markets slide on recession fears
  • Stock Lists

    • 3 defensive stocks to find stability with your money
      June 21, 2022
    • 3 rock stars of the mineral stocks
      June 15, 2022
    • 3 stocks to profit from revenge travel
      June 7, 2022
    • Are tech stocks alive?
      May 31, 2022
    • 3 dividend stocks to fight inflation
      May 24, 2022


  • Get $50 in free trades.


  • Stockchase neither recommends nor promotes any investment strategies.

    About us : Privacy & Terms : Contact us

© Stockchase Inc.
Press enter/return to begin your search